Personalis Inc (PSNL) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Personalis Inc stock $9.80, price $14.80, that is 33.8% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Personalis Inc
PSNL · USExpensive (fair value 34% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.9300 – $22.43 · fair‑value band $7.35 – $12.25 · the $14.80 price screens above the $9.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Personalis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Show moreShow less
The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.
Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.
The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients.
Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Stock analysis
Personalis Inc (PSNL) currently trades at $14.80, while our estimate is $9.80, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $7.35 (bear) to $12.25 (bull), the price of $14.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Personalis Inc reported revenue of $69.6M in FY2025 versus $85.5M in FY2021, a compound −5.0%/yr. Reported net income was −$81.3M in FY2025.
Key figures
Market cap $1.6B Small · P/S ratio 21.4 · EPS (TTM) $−1.16 · Net margin −148% · Return on equity −62.1% · Return on assets (EBIT) −31.3% (5-year average) · Operating margin −139% · Revenue (TTM) $80.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 19% below its 52-week high and 194% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −34%, PSNL screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 4 officers or directors sold shares worth $7.8M and none bought.
- SaleChristopher M HallChief Executive Officer, Director5× since May 28, 2026: 336,571 shares, avg. $13.39$4.5MNov 3, 2026
- SaleAaron TachibanaCFO AND COO7× since Nov 25, 2025: 242,832 shares, avg. $11.75$2.9MSep 18, 2026
- SaleRichard ChenPresident and CMO2× since Jul 15, 2026: 103,998 shares, avg. $15.19$1.6MSep 18, 2026
- SaleStephen Michael MooreSVP and Chief Legal Officer2,068 shares at $16.22$33,543Sep 18, 2026
- BuyTempus AI, Inc.10% owner320,267 shares at $8.55$2.7MDec 22, 2025
Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
PSNL screens overvalued: fair value 34% below the price. Compare with Thermo Fisher Scientific Inc →
Earlier news
- Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
- Personalis downgraded at BTIG on likely Tempus takeover
Compare Personalis Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Illumina, Inc ILMN | $198.00 | $227.71 | +15% | vs PSNL |
| WuXi AppTec Co 603259 | ¥144.41 | ¥164.66 | +14% | vs PSNL |
| IQVIA Holdings IQV | $264.73 | $291.63 | +10% | vs PSNL |
| Thermo Fisher Scientific Inc TMO | $691.33 | $686.04 | −1% | vs PSNL |
| Danaher Corporation DHR | $229.91 | $209.18 | −9% | vs PSNL |
| IDEXX Laboratories, Inc IDXX | $700.65 | $496.48 | −29% | vs PSNL |
| Lonza Group LONN | CHF 670.20 | CHF 259.80 | −61% | vs PSNL |
| Mettler-Toledo International Inc MTD | $1,727 | $655.06 | −62% | vs PSNL |
| Agilent Technologies, Inc A | $172.92 | $64.20 | −63% | vs PSNL |
| Waters Corporation WAT | $453.42 | $91.26 | −80% | vs PSNL |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Personalis Inc (PSNL) overvalued or undervalued?
What is the fair value of PSNL?
What is the quality score of PSNL?
What is the price target for Personalis Inc (PSNL)?
What is the Personalis Inc stock forecast for 2026?
What is the revenue of Personalis Inc (PSNL)?
What is the intrinsic value of Personalis Inc (PSNL)?
Is Personalis Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PSNL?
How much is Personalis Inc worth?
What do the bullish and bearish scenarios say about PSNL?
How solid is the balance sheet of Personalis Inc (PSNL)?
How far is PSNL from its 52-week high?
Which stocks are comparable to Personalis Inc?
Is Personalis Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Personalis Inc (PSNL)?
What should I pay attention to with Personalis Inc right now?
Key figures of Personalis Inc
How large is the market capitalisation of Personalis Inc (PSNL)?
What is the P/S ratio of Personalis Inc (PSNL)?
What are the earnings per share of Personalis Inc (PSNL)?
What is the net margin of Personalis Inc (PSNL)?
What is the return on equity of Personalis Inc (PSNL)?
What is the EBIT return on assets of Personalis Inc (PSNL)?
What is the operating margin of Personalis Inc (PSNL)?
How fast is revenue growing at Personalis Inc (PSNL)?
How much free cash flow does Personalis Inc (PSNL) generate?
How much net cash does Personalis Inc (PSNL) hold?
Watch Personalis Inc in the live analysis
One click puts Personalis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.